Journal of Korean Neurosurgical Society

The Korean Neurosurgical Society (대한신경외과학회)
권호 표지
DOI QR코드

DOI QR Code

Meningiomas with Rhabdoid or Papillary Components : Prognosis and Comparison with Anaplastic Meningiomas

  • Kim, Jeong-Kwon (Department of Neurosurgery, Chonnam National University Hwasun Hospital, Chonnam National University Medical School) ;
  • Jung, Tae-Young (Department of Neurosurgery, Chonnam National University Hwasun Hospital, Chonnam National University Medical School) ;
  • Jung, Shin (Department of Neurosurgery, Chonnam National University Hwasun Hospital, Chonnam National University Medical School) ;
  • Lee, Kyung-Hwa (Department of Pathology, Chonnam National University Hwasun Hospital, Chonnam National University Medical School) ;
  • Kim, Seul-Kee (Department of Radiology, Chonnam National University Hwasun Hospital, Chonnam National University Medical School) ;
  • Lee, Eun Jung (Department of Neurological Surgery, Asan Medical Center, University of Ulsan College of Medicine)
  • Received : 2015.09.30
  • Accepted : 2016.04.06
  • Published : 2016.07.01
Download PDF
⟨ Previous Next ⟩

Abstract

Papillary and rhabdoid meningiomas are pathologically World Health Organization (WHO) grade III. Any correlation between clinical prognosis and pathologic component is not clear. We analyzed the prognoses of patients with meningiomas with a rhabdoid or papillary component compared to those of patients with anaplastic meningiomas. From 1994 to June 2013, 14 anaplastic meningiomas, 6 meningiomas with a rhabdoid component, and 5 meningiomas with papillary component were pathologically diagnosed. We analyzed magnetic resonance imaging (MRI) findings, extent of removal, adjuvant treatment, progression-free survival (PFS), overall survival (OS), and pathologic features of 14 anaplastic meningiomas (group A), 5 meningiomas with a predominant (${\geq}50%$) papillary or rhabdoid component (group B1), and 6 meningiomas without a predominant (<50%) rhabdoid or papillary component (group B2). Homogeneous enhancement on MRI was associated with improved PFS compared to heterogeneous enhancement (p=0.025). Depending on pathology, the mean PFS was $134.9{\pm}31.6\;months$ for group A, $46.6{\pm}13.4\;months$ for group B1, and $118.7{\pm}19.2\;months$ for group B2. The mean OS was $138.5{\pm}24.6\;months$ for group A and $59.7{\pm}16.8\;months$ for group B1. All recurrent tumors were of the previously diagnosed pathology, except for one tumor from group B1, which recurred as an atypical meningioma without a papillary component. Group B1 tumors showed a more aggressive behavior than group B2 tumors. In group B2 cases, the pathologic findings of non-rhabdoid/papillary portion could be considered for further adjuvant treatment.

Keywords

References

  1. Al-Habib A, Lach B, Al Khani A : Intracerebral rhabdoid and papillary meningioma with leptomeningeal spread and rapid clinical progression. Clin Neuropathol 24 : 1-7, 2005
  2. Durand A, Labrousse F, Jouvet A, Bauchet L, Kalamarides M, Menei P, et al. : WHO grade II and III meningiomas : a study of prognostic factors. J Neurooncol 95 : 367-375, 2009 https://doi.org/10.1007/s11060-009-9934-0
  3. Hug EB, Devries A, Thornton AF, Munzenride JE, Pardo FS, Hedley-Whyte ET, et al. : Management of atypical and malignant meningiomas : role of high-dose, 3D-conformal radiation therapy. J Neurooncol 48 : 151-160, 2000 https://doi.org/10.1023/A:1006434124794
  4. Karabagli P, Karabagli H, Yavas G : Aggressive rhabdoid meningioma with osseous, papillary and chordoma-like appearance. Neuropathology 34 : 475-483, 2014 https://doi.org/10.1111/neup.12122
  5. Kasuya H, Kubo O, Tanaka M, Amano K, Kato K, Hori T : Clinical and radiological features related to the growth potential of meningioma. Neurosurg Rev 29 : 293-296; discussion 296-297, 2006 https://doi.org/10.1007/s10143-006-0039-3
  6. Kepes JJ, Moral LA, Wilkinson SB, Abdullah A, Llena JF : Rhabdoid transformation of tumor cells in meningiomas : a histologic indication of increased proliferative activity : report of four cases. Am J Surg Pathol 22 : 231-238, 1998 https://doi.org/10.1097/00000478-199802000-00012
  7. Kim JP, Park BJ, Lim YJ : Papillary meningioma with leptomeningeal seeding. J Korean Neurosurg Soc 49 : 124-127, 2011 https://doi.org/10.3340/jkns.2011.49.2.124
  8. Kliese N, Gobrecht P, Pachow D, Andrae N, Wilisch-Neumann A, Kirches E, et al. : miRNA-145 is downregulated in atypical and anaplastic meningiomas and negatively regulates motility and proliferation of meningioma cells. Oncogene 32 : 4712-4720, 2013 https://doi.org/10.1038/onc.2012.468
  9. Koenig MA, Geocadin RG, Kulesza P, Olivi A, Brem H : Rhabdoid meningioma occurring in an unrelated resection cavity with leptomeningeal carcinomatosis. Case report. J Neurosurg 102 : 371-375, 2005 https://doi.org/10.3171/jns.2005.102.2.0371
  10. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK : WHO Classification of tumours of the central nervous system, ed 3. Lyon : IARC, 2007, pp164-172
  11. Mahmood A, Caccamo DV, Tomecek FJ, Malik GM : Atypical and malignant meningiomas : a clinicopathological review. Neurosurgery 33 : 955-963, 1993
  12. Milosevic MF, Frost PJ, Laperriere NJ, Wong CS, Simpson WJ : Radiotherapy for atypical or malignant intracranial meningioma. Int J Radiat Oncol Biol Phys 34 : 817-822, 1996 https://doi.org/10.1016/0360-3016(95)02166-3
  13. Modha A, Gutin PH : Diagnosis and treatment of atypical and anaplastic meningiomas : a review. Neurosurgery 57 : 538-550; discussion 538-550, 2005 https://doi.org/10.1227/01.NEU.0000170980.47582.A5
  14. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. : Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5 : 649-655, 1982 https://doi.org/10.1097/00000421-198212000-00014
  15. Rogerio F, de Araujo Zanardi V, Ribeiro de Menezes Netto J, de Souza Queiroz L : Meningioma with rhabdoid, papillary and clear cell features : case report and review of association of rare meningioma variants. Clin Neuropathol 30 : 291-296, 2011 https://doi.org/10.5414/NP300408
  16. Simpson D : The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry 20 : 22-39, 1957 https://doi.org/10.1136/jnnp.20.1.22
  17. Sun SQ, Hawasli AH, Huang J, Chicoine MR, Kim AH : An evidencebased treatment algorithm for the management of WHO Grade II and III meningiomas. Neurosurg Focus 38 : E3, 2015
  18. Verheggen R, Finkenstaedt M, Bockermann V, Markakis E : Atypical and malignant meningiomas : evaluation of different radiological criteria based on CT and MRI. Acta Neurochir Suppl 65 : 66-69, 1996
  19. Vinchon M, Ruchoux MM, Lejeune JP, Assaker R, Christiaens JL : Carcinomatous meningitis in a case of anaplastic meningioma. J Neurooncol 23 : 239-243, 1995 https://doi.org/10.1007/BF01059955
  20. Wu YT, Ho JT, Lin YJ, Lin JW : Rhabdoid papillary meningioma : a clinicopathologic case series study. Neuropathology 31 : 599-605, 2011 https://doi.org/10.1111/j.1440-1789.2011.01201.x
  21. Zhao P, Hu M, Zhao M, Ren X, Jiang Z : Prognostic factors for patients with atypical or malignant meningiomas treated at a single center. Neurosurg Rev 38 : 101-107; discussion 107, 2015 https://doi.org/10.1007/s10143-014-0558-2

Cited by

  1. Orbital malignant meningioma: a unique presentation of a rare entity vol.37, pp.6, 2018, https://doi.org/10.1080/01676830.2018.1437189
  2. Clinical and histopathological predictors of outcome in malignant meningioma vol.43, pp.2, 2020, https://doi.org/10.1007/s10143-019-01093-5